NASDAQ:BIAF bioAffinity Technologies (BIAF) Stock Price, News & Analysis → 😱 This phenomenon is smashing regular market gains (From MillPub) (Ad) Free BIAF Stock Alerts $2.45 0.00 (0.00%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$2.36▼$2.5550-Day Range$1.42▼$3.0052-Week Range$0.95▼$3.62Volume79,844 shsAverage Volume177,758 shsMarket Capitalization$28.20 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get bioAffinity Technologies alerts: Email Address Ad Porter & CompanyTrump’s last act as President You’ve probably never heard of Executive Order #13972. Signed by President Trump just days before leaving office, it greenlit what could be the most revolutionary technology of the decade… yet it has nothing to do with AI, blockchain, or mRNA vaccines. For the full story, click here. About bioAffinity Technologies Stock (NASDAQ:BIAF)bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.Read More BIAF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIAF Stock News HeadlinesMay 2, 2024 | americanbankingnews.combioAffinity Technologies (BIAF) vs. The Competition Head-To-Head ContrastApril 30, 2024 | americanbankingnews.combioAffinity Technologies (BIAF) versus The Competition Financial AnalysisMay 2, 2024 | Porter & Company (Ad)Trump’s last act as President You’ve probably never heard of Executive Order #13972. Signed by President Trump just days before leaving office, it greenlit what could be the most revolutionary technology of the decade… yet it has nothing to do with AI, blockchain, or mRNA vaccines. April 29, 2024 | americanbankingnews.comAnalyzing bioAffinity Technologies (BIAF) and Its RivalsApril 29, 2024 | americanbankingnews.comFinancial Contrast: bioAffinity Technologies (BIAF) and The CompetitionApril 28, 2024 | americanbankingnews.comFinancial Review: bioAffinity Technologies (BIAF) and Its CompetitorsApril 27, 2024 | americanbankingnews.comFinancial Survey: bioAffinity Technologies (BIAF) vs. Its PeersApril 27, 2024 | americanbankingnews.comHead to Head Comparison: bioAffinity Technologies (BIAF) versus The CompetitionMay 2, 2024 | Porter & Company (Ad)Trump’s last act as President You’ve probably never heard of Executive Order #13972. Signed by President Trump just days before leaving office, it greenlit what could be the most revolutionary technology of the decade… yet it has nothing to do with AI, blockchain, or mRNA vaccines. April 26, 2024 | investing.combioAffinity Technologies appoints VP to enhance diagnosticsApril 26, 2024 | americanbankingnews.combioAffinity Technologies (BIAF) and Its Rivals Critical SurveyApril 25, 2024 | americanbankingnews.comReviewing bioAffinity Technologies (BIAF) & Its CompetitorsApril 25, 2024 | americanbankingnews.comFinancial Contrast: bioAffinity Technologies (BIAF) versus Its CompetitorsApril 24, 2024 | businesswire.combioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of GrowthApril 23, 2024 | americanbankingnews.comReviewing bioAffinity Technologies (BIAF) and Its CompetitorsApril 22, 2024 | americanbankingnews.comFinancial Analysis: bioAffinity Technologies (BIAF) vs. Its PeersApril 9, 2024 | finance.yahoo.combioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer ScreeningApril 9, 2024 | businesswire.combioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer ScreeningMarch 8, 2024 | finance.yahoo.combioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private PlacementMarch 8, 2024 | finance.yahoo.comWallachbeth Capital Announces Closing of bioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private PlacementMarch 6, 2024 | msn.comNasdaq Gains 100 Points; Campbell Soup Earnings Top ViewsMarch 6, 2024 | marketwatch.comBioAffinity Technologies Shares Plummet After Stock SaleMarch 6, 2024 | msn.comWhy BioAffinity Technologies (BIAF) Shares Are Down 50%March 6, 2024 | msn.comBioAffinity Technologies to raise $2.5M from stock offering and private placementMarch 6, 2024 | finance.yahoo.comWallachBeth Capital Announces Pricing of BioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private PlacementMarch 6, 2024 | businesswire.combioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private PlacementMarch 1, 2024 | finance.yahoo.comHere's Why We're A Bit Worried About bioAffinity Technologies' (NASDAQ:BIAF) Cash Burn SituationSee More Headlines Receive BIAF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bioAffinity Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today5/02/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryN/A Current SymbolNASDAQ:BIAF CUSIPN/A CIK1712762 Webwww.bioaffinitytech.com Phone210-698-5334FaxN/AEmployees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,940,000.00 Net Margins-313.34% Pretax Margin-312.64% Return on Equity-107.20% Return on Assets-84.10% Debt Debt-to-Equity Ratio0.17 Current Ratio1.77 Quick Ratio1.76 Sales & Book Value Annual Sales$2.53 million Price / Sales11.15 Cash FlowN/A Price / Cash FlowN/A Book Value$0.51 per share Price / Book4.80Miscellaneous Outstanding Shares11,510,000Free Float6,413,000Market Cap$28.20 million OptionableNot Optionable Beta3.93 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Steven Girgenti (Age 78)Founder & Executive Chairman of the Board Comp: $113.75kMs. Maria Zannes J.D. (Age 68)Founder, President, CEO & Director Comp: $299.17kMs. Julie Anne OvertonDirector of CommunicationsMr. Dallas J. ColemanNational Director of SalesDr. William Bauta Ph.D.Senior Vice President of TherapeuticsKey CompetitorsAIkido PharmaNASDAQ:AIKIInotivNASDAQ:NOTVFemasysNASDAQ:FEMYEvogeneNASDAQ:EVGNAprea TherapeuticsNASDAQ:APREView All Competitors BIAF Stock Analysis - Frequently Asked Questions How have BIAF shares performed in 2024? bioAffinity Technologies' stock was trading at $1.4705 on January 1st, 2024. Since then, BIAF shares have increased by 66.6% and is now trading at $2.45. View the best growth stocks for 2024 here. Are investors shorting bioAffinity Technologies? bioAffinity Technologies saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 240,900 shares, an increase of 337.2% from the March 31st total of 55,100 shares. Based on an average daily volume of 221,200 shares, the short-interest ratio is presently 1.1 days. Currently, 4.4% of the company's shares are short sold. View bioAffinity Technologies' Short Interest. When is bioAffinity Technologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our BIAF earnings forecast. How were bioAffinity Technologies' earnings last quarter? bioAffinity Technologies, Inc. (NASDAQ:BIAF) posted its quarterly earnings results on Monday, April, 1st. The company reported ($0.26) earnings per share for the quarter. The firm had revenue of $2.21 million for the quarter. bioAffinity Technologies had a negative trailing twelve-month return on equity of 107.20% and a negative net margin of 313.34%. When did bioAffinity Technologies IPO? bioAffinity Technologies (BIAF) raised $8 million in an initial public offering (IPO) on Thursday, September 1st 2022. The company issued 1,300,000 shares at a price of $6.00-$6.25 per share. WallachBeth Capital acted as the underwriter for the IPO and Craft Capital Management was co-manager. How do I buy shares of bioAffinity Technologies? Shares of BIAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BIAF) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics😱 This phenomenon is smashing regular market gainsMillPubYour bank is lying to you.MyBankTrackerDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bioAffinity Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
